金叶败毒颗粒治疗轻症COVID-19的临床疗效
本研究为前瞻性队列试验,纳入830例轻症COVID-19患者,随机接受金叶败毒颗粒或中药安慰剂治疗7天。结果显示金叶败毒颗粒组7天RNA转阴率显著高于安慰剂组(89.8% vs 82.6%,P=0.003),且核酸转阴时间和住院时间均缩短,未见重症转化及严重不良事件。
要点
- 金叶败毒颗粒可提高轻症COVID-19患者7天RNA转阴率。
- 金叶败毒颗粒缩短核酸转阴时间及住院时间。
- 年龄≤60岁亚组中金叶败毒颗粒促进RNA转阴。
核心结论
- 金叶败毒颗粒可能是治疗轻症COVID-19的潜在药物,有助于提高RNA转阴率、缩短核酸转阴时间和住院时间。
主要发现
- 金叶败毒颗粒组7天RNA转阴率89.8%(380/423)显著高于安慰剂组82.6%(304/368),P=0.003。
- 金叶败毒颗粒组SARS-CoV-2核酸转阴时间中位数4.0(3.0,6.0)天,短于安慰剂组5.0(4.0,7.0)天,P<0.001。
- 金叶败毒颗粒组住院时间中位数6.0(4.0,8.0)天,短于安慰剂组7.0(5.0,9.0)天,P<0.001。
- 两组临床症状均有明显改善,但组间差异无统计学意义;两组均无重症转化及严重不良事件报告。
- 年龄≤60岁亚组中,金叶败毒颗粒促进SARS-CoV-2 RNA转阴(HR=1.242;95% CI:1.069-1.444,P<0.001)。
关键数值与推荐
- 金叶败毒颗粒组7天RNA转阴率89.8%(380/423),安慰剂组82.6%(304/368),P=0.003。
- 核酸转阴时间中位数:金叶败毒颗粒组4.0(3.0,6.0)天 vs 安慰剂组5.0(4.0,7.0)天,P<0.001。
- 住院时间中位数:金叶败毒颗粒组6.0(4.0,8.0)天 vs 安慰剂组7.0(5.0,9.0)天,P<0.001。
- 年龄≤60岁亚组RNA转阴HR=1.242;95% CI:1.069-1.444,P<0.001。
临床怎么用
- 对于轻症COVID-19患者,可考虑使用金叶败毒颗粒以促进病毒清除和缩短住院时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Jingyin granules (JY), one patented Chinese herbal formula, have been advised for treating coronavirus disease 2019 (COVID-19) in China. As of now, the safety and effectiveness of JY in treating COVID-19 patients were still to be evaluated. PURPOSE: To investigate the safety and clinical effectiveness of JY in treating mild COVID-19 patients. STUDY DESIGN: We carried out a prospective cohort study, as the highly infectious COVID-19 omicron variant ranged in Shanghai (ClinicalTrial.gov registration number: ChiCTR2200058692). METHODS: Participants infected with COVID-19, who were diagnosed as mild cases, were assigned to receive either JY (JY group) or traditional Chinese medicine placebo (placebo group) orally for 7 days. The primary clinical indicators were the RNA negative conversion rate (NCR) and the incidence of severe cases. The secondary clinical indicators were the negative conversion time (NCT), inpatient length of stay (ILOS), and the disappearance rates of clinical symptoms. RESULTS: Nine hundred participants were recruited in this clinical trial study, and 830 patients met the eligibility criteria. Seven hundred and ninety-one patients, accomplished the following-up assessment, including 423 cases of JY group and 368 cases of placebo group. NCR in JY group at 7-day posttreatment was considerably greater compared with placebo group (89.8% [380/423] vs 82.6% [304/368], P = 0.003). None of the patients with mild COVID-19 developed into severe cases. The median NCT of SARS-CoV-2 and ILOS in JY group were lesser than that in placebo group (4.0 [3.0,6.0]vs 5.0 [4.0,7.0] days, P < 0.001; 6.0 [4.0, 8.0] vs 7.0 [5.0, 9.0] days, P < 0.001). In both groups, the obvious improvement in clinical symptoms was observed, but the difference was not significant. In the subgroup of age ≤ 60 years, JY promoted SARS-CoV-2 RNA negative conversion (HR=1.242; 95% CI: 1.069-1.444, P < 0.001). No patients in both groups were reported as the case of serious adverse event. CONCLUSION: JY maybe the potential medicine for treating mild COVID-19 patients, which had beneficial effects on increasing NCR, and shortening NCT and ILOS.
引用
- Chen B, Yu X, Zhang L, et al. Clinical efficacy of Jingyin granules, a Chinese patent medicine, in treating patients infected with coronavirus disease 2019. Phytomedicine. 2022. PMID: 36288651. doi:10.1016/j.phymed.2022.154496
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。